Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02641444 · ClinicalTrials.gov registry record
Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- 5
- Enrollment target
NCT02641444: Clinical Trial study, sponsored by University of North Carolina, Chapel Hill.
NCT02641444 is a clinical trial that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02641444 was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out how the drugs Truvada® (tenofovir/emtricitabine), Isentress® (raltegravir), Reyataz® (atazanavir), Sustiva® (efavirenz), and Selzentry® (maraviroc) get into the intestines and the female genital tract. All of these drugs are very effective at reducing the number of HIV viruses in the blood, however it is unknown how the drugs move around inside tissues where HIV might be hiding. This study will determine specifically where in the tissue the drug and the HIV are located through the use of a new technology that takes creates a picture of the tissue. This information will help scientists determine the best way to make new drugs to target the hidden HIV in tissue.
Primary Outcome
Tissues collected during inpatient stay will be frozen for later analysis (i.e. MSI-derived images of TFV, FTC, RAL, ATZ, EFV, and MVC localization within tissue slices.) to be completed within 6 months of tissue collection.
Interventions
- PROCEDURE Blood plasma collection
- PROCEDURE Cervical and Vaginal Biopsy
- PROCEDURE Colonoscopy with Ileal and Rectal Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-04-13 |
| Est. Completion | 2017-08-29 |
Why NCT02641444 stopped before completion
NCT02641444 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Blood plasma collection is the first listed.
NCT02641444 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02641444 about?
NCT02641444 is a clinical study titled "Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects". The purpose of this research study is to find out how the drugs Truvada® (tenofovir/emtricitabine), Isentress® (raltegravir), Reyataz® (atazanavir), Sustiva® (efavirenz), and Selzentry® (maraviroc) get into the intestines and the female genital tract. All of these drugs are very effective at reducin...
What is the current status of trial NCT02641444?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2016-04-13. Estimated completion is 2017-08-29.
What interventions are being tested in trial NCT02641444?
The interventions under investigation include: Blood plasma collection (PROCEDURE), Cervical and Vaginal Biopsy (PROCEDURE), Colonoscopy with Ileal and Rectal Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02641444?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI